Artgen Biotech PJSC (MIC:ABIO) Net Income From Continuing Operations : ₽29 Mil (TTM As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Artgen Biotech PJSC's net income from continuing operations for the six months ended in Jun. 2023 was ₽36 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was ₽29 Mil.

Artgen Biotech PJSC Net Income From Continuing Operations Historical Data

The historical data trend for Artgen Biotech PJSC's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC Net Income From Continuing Operations Chart

Artgen Biotech PJSC Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Income From Continuing Operations

Get a 7-Day Free Trial

-18.24

111.34

103.40

33.55

23.08

Artgen Biotech PJSC Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Net Income From Continuing Operations	Get a 7-Day Free Trial															25.85	7.70	29.93	-6.85	36.07

Artgen Biotech PJSC Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₽29 Mil.

Artgen Biotech PJSC (MIC:ABIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Prospect of the 60th Anniversary, Moscow, RUS, 117036

Website

https://www.hsci.ru

Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.